Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $21.76 in the prior trading day, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) closed at $20.47, down -5.93%. In other words, the price has decreased by -$5.93 from its previous closing price. On the day, 1.52 million shares were traded. NAMS stock price reached its highest trading level at $22.06 during the session, while it also had its lowest trading level at $19.54.
Ratios:
Our goal is to gain a better understanding of NAMS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.08 and its Current Ratio is at 8.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $48.
On March 14, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $35.Scotiabank initiated its Sector Outperform rating on March 14, 2024, with a $35 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 26 ’25 when Topper James N bought 1,135 shares for $22.49 per share. The transaction valued at 25,521 led to the insider holds 3,013,569 shares of the business.
Michael H. Davidson bought 12,258 shares of NAMS for $286,960 on Mar 26 ’25. On Mar 26 ’25, another insider, Douglas F Kling, who serves as the Affiliate of the company, bought 16,539 shares for $23.41 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 2389626880 and an Enterprise Value of 1414228608. For the stock, the TTM Price-to-Sale (P/S) ratio is 49.34 while its Price-to-Book (P/B) ratio in mrq is 2.92. Its current Enterprise Value per Revenue stands at 31.039 whereas that against EBITDA is -8.027.
Stock Price History:
The Beta on a monthly basis for NAMS is -0.04, which has changed by -0.043457925 over the last 52 weeks, in comparison to a change of 0.077997446 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $15.19. The 50-Day Moving Average of the stock is -5.56%, while the 200-Day Moving Average is calculated to be 1.67%.
Shares Statistics:
The stock has traded on average 874.43K shares per day over the past 3-months and 1080180 shares per day over the last 10 days, according to various share statistics. A total of 108.06M shares are outstanding, with a floating share count of 57.95M. Insiders hold about 47.10% of the company’s shares, while institutions hold 48.02% stake in the company. Shares short for NAMS as of 1741910400 were 4342156 with a Short Ratio of 4.97, compared to 1739491200 on 2911595. Therefore, it implies a Short% of Shares Outstanding of 4342156 and a Short% of Float of 5.9499998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
